Innate Pharma IPHA
NASDAQ IPHA
$1.52 -0.05 (-3.21%)
As of: Oct 22, 2026 · 9:43 AM EDT

Innate Pharma (IPHA) Interest Expenses (2019)

Updated

Innate Pharma's Interest Expenses came in at -$1.62 million for the quarter ended Jun 30, 2026, compared with -$3.17 million a year earlier.

Analysis

Innate Pharma (IPHA) Interest Expenses (2019) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Innate Pharma reported Interest Expenses of -$12.67 million; for the year ended Dec 31, 2025, it came in at -$3.53 million.

  • Going back by year, Interest Expenses was -$4.3 million in the year ended Dec 31, 2024, -$1.98 million in the year ended Dec 31, 2023, -$5.61 million in the year ended Dec 31, 2022 and -$4.57 million in the year ended Dec 31, 2021.
  • The figure for the quarter ended Jun 30, 2026 represents the highest quarterly Interest Expenses since the quarter ended Jun 30, 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Int Expense (Qtr)
1 Eli Lilly 1,160.65 Bn 1,129.23 Bn 19.71 Bn -
2 Johnson & Johnson 633.19 Bn 551.72 Bn 17.26 Bn 281.00 Mn
3 AbbVie 501.90 Bn 475.01 Bn 12.70 Bn -
4 Merck 377.07 Bn 331.45 Bn 12.21 Bn -
5 Novartis Ag 302.35 Bn 266.34 Bn 11.24 Bn 462.00 Mn
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn 435.00 Mn
7 Amgen 240.68 Bn 196.07 Bn 7.24 Bn 673.00 Mn
8 Gilead Sciences 193.20 Bn 167.40 Bn 6.22 Bn 247.00 Mn
9 Pfizer 172.14 Bn 118.78 Bn 10.94 Bn -
10 Innate Pharma 136.18 Mn -71.02 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2019 -2.17 Mn
API Access

Innate Pharma Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=interest-expenses&ticker=IPHA&period=max&api_key=YOUR_API_KEY